These included a patient with ovarian/peritoneal cancer (BRCA1 mutation, BRCA2 wild type) who had a PR for 7 months, a second patient with ovarian/peritoneal cancer (BRCA1 and BRCA2 wild type) who had a PR for 5 months, and a patient with breast cancer (BRCA1 mutation, BRCA2 not tested) who had a PR for 3 months. This evidence concerns the gene BRCA1 and breast carcinoma.